Analyst Price Targets — KPTI
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 17, 2025 12:01 pm | — | Goldman Sachs | $12.00 | $6.33 | StreetInsider | Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick |
| December 17, 2025 12:01 pm | — | Piper Sandler | $12.00 | $6.33 | StreetInsider | Piper Sandler Highlights Karyopharm Therapeutics (KPTI) As a 2026 Top Pick |
| November 4, 2025 2:49 pm | Brian Abrahams | RBC Capital | $19.00 | $5.60 | TheFly | Karyopharm price target lowered to $19 from $30 at RBC Capital |
| October 13, 2025 10:10 am | Robert Burns | H.C. Wainwright | $15.00 | $5.50 | TheFly | Karyopharm upgraded to Buy from Neutral at H.C. Wainwright |
| October 9, 2025 11:13 am | — | Robert W. Baird | $21.00 | $5.90 | TheFly | Karyopharm price target lowered to $21 from $25 at Baird |
| October 8, 2025 6:56 pm | — | Leerink Partners | $6.00 | $5.91 | TheFly | Karyopharm price target lowered to $6 from $8 at Leerink |
| June 10, 2024 5:39 am | Brian Abrahams | RBC Capital | $3.00 | $0.95 | StreetInsider | RBC Capital Reiterates Outperform Rating on Karyopharm Therapeutics (KPTI) |
| January 10, 2023 4:30 am | — | Leerink Partners | $5.00 | $2.84 | Benzinga | SVB Leerink Maintains Market Perform on Karyopharm Therapeutics, Lowers Price Target to $5 |
| August 23, 2022 11:57 am | Collen Kusy | Robert W. Baird | $14.00 | $5.56 | Pulse 2.0 | Karyopharm (KPTI) Stock: $14 Target And Outperform Rating |
| March 10, 2022 12:00 am | Brian Abrahams | RBC Capital | $8.00 | $6.49 | Pulse 2.0 | Karyopharm Therapeutics (KPTI) Stock: $8 Price Target And Sector Perform Rating |
Latest News for KPTI
NEWTON, Mass., March 2, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 1,450 restricted stock units (RSUs) to two newly-hired employees.
The consensus price target hints at a 56.1% upside potential for Karyopharm Therapeutics (KPTI). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Karyopharm Therapeutics Inc. (KPTI) Q4 2025 Earnings Call Transcript
Karyopharm Therapeutics (KPTI) came out with a quarterly loss of $2.23 per share versus the Zacks Consensus Estimate of a loss of $2.26. This compares to a loss of $3.6 per share a year ago.
– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Top-Line Data from the Phase 3 XPORT-EC-042 Trial in Endometrial Cancer on Track for Mid-2026 – – Total Revenue was $146 Million and U.S. XPOVIO® (selinexor) Net Product Revenue was $115 Million for Full Year 2025 – – Company Provides Full-Year 2026 Total Revenue Guidance of $130 Million to $150 Million Including U.S. XPOVIO…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for KPTI.
U.S. House Trading
No House trades found for KPTI.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.